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http://dx.doi.org/10.1016/j.jfma.201DiGeorge syndrome is not really a rare disease. A microdeletion of chromosome 22q11.2 is
found in most patients. Sharing the same genetic cause, a wide spectrum of clinical manifes-
tations such as conotruncal anomaly face syndrome, Cayler cardiofacial syndrome, and velo-
cardiofacial syndrome have been reported. Classic characteristics are cardiac defects,
abnormal facial features, thymic hypoplasia, cleft palate, and hypocalcemia. We report a 6-
year-old female child presenting with generalized seizure resulting from hypocalcemia. She
had no cardiac defects and no hypocalcemia episode in neonatal stage, and had been said
to be normal before by her parents until the diagnosis was made. This highlights the impor-
tance of extracardiac manifestations in the diagnosis of DiGeorge syndrome, and many
affected patients may be underestimated with minor facial dysmorphism. As health practi-
tioners, it is our duty to identify the victims undermined in the population, and start thorough
investigations and the following rehabilitation as soon as possible. Multiplex ligation-
dependent probe amplification is a rapid, reliable, and economical alternative for the diag-
nosis of 22q11.2 deletion.
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DiGeorge syndrome (DGS) is a developmental disorder
derived from embryonic defects of the third and fourth
pharyngeal pouches.1 A microdeletion of chromosome
22q11.2 is found in most patients. Sharing the same genetic
cause, a wide spectrum of clinical manifestations such as
conotruncal anomaly face syndrome, Cayler cardiofacial
syndrome, and velocardiofacial syndrome have previously
been reported.2 Wilson et al3 proposed the term
“CATCH22” to refer to the group as a whole in 1993.
Characteristic faces include tubular nose, hooded eyes,
and small mouth. We report a 6-year-old female child
presenting with a generalized seizure resulting from hypo-
calcemia. No heart murmur had been discovered previ-
ously, and the facial phenotypical features were so trivial
that she had been thought to be normal by her parents until
the diagnosis was made. In order to make an earlier diag-
nosis, it is important for clinicians to be aware of this
syndrome and to familiarize themselves with related
extracardiac manifestations. DGS is traditionally diagnosed
with fluorescence in situ hybridization (FISH); however,
other diagnostic modalities have been suggested recently,
and multiplex ligation-dependent probe amplification
(MLPA) is one of these alternatives.
Case report
A 6-year-old girl was admitted to our emergency depart-
ment due to seizure attack in the morning. It lasted for
about 3 minutes, which involved loss of consciousness,
upward gazing, and tonic convulsions of the upper limbs.
Hypocalcemia with a total calcium concentration of
5.1 mg/dL was found, and brain CT showed calcifications of
bilateral globus pallidus (Fig. 1) and maxillary sinusitis.
Tracing back the patient’s history, she was born to
a G2P1A1 mother via normal spontaneous delivery at 40Figure 1 Calcifications of bilateral globus pallidus (black
arrows).gestational weeks with a birth body weight of 2800 g. There
was no maternal infection and no family history of heredi-
tary, neurological, or systemic diseases. Vaccinations had
been received on schedule. According to the statements
made by her family, she was robust before except a mild
speech delay and poor school performance. Similar and
brief seizure attacks were noted at the ages of 1 and 3
years, respectively.
During the physical examination, the patient was shy
and introverted. Consciousness was clear and body
temperature was 37.7C. Vital signs were stable as follows:
heart rate was 110/min, respiratory rate 22/min, and blood
pressure 103/66 mmHg. Breathing sounds were clear and
heart beats were regular, without murmur. Neurological
findings were negative. The patient was then inspected
closely for congenital anomalies. Her face was unremark-
able in the first glance, but bifid uvula was found when
looking into her mouth. By further examining the facial
landmarks, she had short philtrum (<3rd percentile),
bulbous nose tip, micrognathia, low set ears, and hyper-
telorism (Figs. 2 and 3). Both outer and inner canthal
distances were beyond the 97th percentile; interpupillary
distance was beyond the 75th percentile. Height (112 cm)
and weight (18 kg) were all within normal limits.
The laboratory findings were as follows: the peripheral
leukocyte count was 8.15  103/L, hemoglobin concentra-
tion 12.6 g/dL, and platelet count 150  103. Biochemical
evaluation included sodium 142 mmol/L, potassium
3.2 mmol/L, magnesium 1.9 mg/dL, and creatinine
0.35 mg/dL. Chest X-ray showed no cardiomegaly, andFigure 2 Facial dysmorphism with hypertelorism, short
philtrum, and bulbous nose tip.
Figure 3 Low set ears and micrognathia.
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tions revealed low parathyroid hormone (<3 pg/mL), raised
serum phosphate (5.3 mg/dL), normal serum albumin
(4.1 g/dL), and normal alkaline phosphatase (100 IU/L) and
active vitamin D (59 pg/mL) levels. Electroencephalography
showed mild diffuse cerebral dysfunction in terms of
excessive slow waves for her age. Electrocardiogram and
echocardiogram were performed, but were unremarkable.Figure 4 Chromosome 22q11.2 deletions analyzed by multiple
LCR22-C).Immunological studies revealed mild T-cell deficiency with
CD3 46.3% (67e81%), CD4 19.3% (38e46%), CD8 17.6%
(30e40%), CD19 31.5% (8e32%), CD16 þ 56 19.6%
(5.6e31%), active T cells 4.4% (8e15%), and normal levels of
immunoglobulin (IgG 1240 mg/dL, IgA 192 mg/dL, and IgM
115 mg/dL). Renal echogram was negative. Under the
impression of DGS, a genetic study using MLPA was
arranged, which confirmed the microdeletion of her chro-
mosome 22q11.2 (from LCR22-A to LCR22-C; Fig. 4).
Intravenous calcium gluconate was given immediately
after the detection of hypocalcemia. The patient respon-
ded well to our therapy, and total serum calcium level
increased gradually to 8.1 mg/dL on the 3rd day of admis-
sion. Medication was switched to oral calcium carbonate
and calcitriol. Speech therapy was also commenced. She
was then discharged and regularly followed up at our
jointed outpatient department of endocrinologist, psychi-
atrist, speech therapist, and neurologist. Serum total
calcium, and urine calcium and creatinine levels were
checked in every visit to monitor calcium supplementation
and prevent hypercalciuria. No additional seizures were
found 9 months after discharge.
Discussion
DGS was first described by Angelo Mario DiGeorge in 1965.4
Incidence of chromosome 22q11 microdeletion varies fromx ligation-dependent probe amplification (from LCR22-A to
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4000 and 1 per 9700 live births.6 The majority of cases
occur de novo, but it is estimated that 5e25% of cases are
inherited from a parent in an autosomal-dominant
manner.7 However, patients with mild manifestations
could be undiagnosed in the absence of cardiovascular
malformations. In addition, since microdeletion can be
found only by using certain modern techniques, it might
have been underestimated initially due to the use of older
cytogenetic studies. The deletion is generally about 3 Mb
and contains numerous genes. The smaller region, which is
responsible for phenotypic expressions, has been termed
the DiGeorge critical region (DGCR). A single gene called
ubiquitin-fusion-degradation-1-like (UFD1L) in DGCR is
found constantly deleted in patients with DGS (88%) and
velocardiofacial syndrome (76%).2 The microdeletion
occurs up to 89% of phenotypic features typical of DGS and
makes up to 15% of all congenital heart diseases.8 The
associated phenotype is so variable that more than 150
manifestations have been acknowledged by the Velo-
Cardio-Facial Syndrome Educational Foundation.9 Facial
dysmorphism includes elongated face with a short phil-
trum, small and fish-like mouth, bifid uvula, high-arched
palate, small mandible, bulbous nose tip, small and
hooded eyes, hypertelorism, and narrow palpebral fissures.
Ears may be microtic, low set, or overfolded. The most
common types of cardiovascular malformation were
tetralogy of Fallot (22e35%), interrupted aortic arch
(15e19%), ventricular septal defect (13e18%), truncus
arteriosus (7e12%), and vascular ring (5%).10,11 About 90%
of del22q11 cases are thought to occur sporadically, but
family occurrence for such patients has been well docu-
mented.12 Although cardiac defects have been reported in
up to 75% of the cases of DGS,13 no cardiovascular abnor-
mality was noted in our patient. As a matter of fact, the
trivial findings of her facial anomalies did not arouse the
suspicion of clinicians even though she had received more
than six scheduled physical checkups. Our case highlights
the importance of extracardiac manifestations as a clue to
the final diagnosis. DGS is usually diagnosed using FISH with
commercial probes. It is extremely accurate but also
quite expensive, and limited to only one single-target
sequence. Recently, more sophisticated techniques
such as array comparative genomic hybridization,
genomewide microarrays, and MLPA will eventually
replace FISH studies in most laboratories.14 MLPA has been
designed to detect many structural rearrangements and
aneuploidies in a single essay, which allows up to 40
different probes in a single tube. It was shown to be
a rapid, reliable, economical, and high-throughput method
for the diagnosis of 22q11.2 deletion syndrome by Fer-
nandez et al in 2005.15
Endocrinopathies are common in patients with
a 22q11.2 deletion. Hypoparathyroidism, hypothyroidism,
and growth hormone deficiency are the problems that
require particular attention.16 Among these, hypopara-
thyroidism was the first hormonal disturbance recognized
in DGS and documented by aplasia and hypoplasia of the
parathyroid glands at surgery or autopsy.17 The prevalence
of hypocalcemia in 22q11.2 deletion varies in different
reports. In a very large European study, Ryan et al13 found
hypocalcemia in 203 of 340 patients (60%), in whom 39%presented with seizures and 70% were found to have
transient hypocalcemia. Hypocalcemia can occur tran-
siently in neonatal stage with symptoms of seizures,
tremors, or tetany,18 mainly due to low parathyroid
reserve and abrupt cessation of maternal calcium supply
after birth. Hypocalcemia generally improves over the
first year of life as the parathyroid glands become
hypertrophic. However, recurrence of hypoparathyroidism
may be precipitated by increased metabolic demand and
acute illness in adolescence and adulthood.19 Our
patient’s seizure in this attack was clearly resulting from
hypocalcemia and hypoparathyroidism. Although there
were no investigations into the prior two attacks at the
age of 1 and 3 years, it is reasonable to suspect that they
shared the same etiology. Calcifications in basal ganglia
detected in computerized tomography can be used as an
adjuvant evidence of chronic hypocalcemia. Our case
suggests that hypocalcemia in DGS can occur at any time
during childhood but does not always start from neonatal
period.
Immunodeficiency has been reported in 80% of patients
with 22q11 syndrome.20 As a result of thymic hypoplasia,
cell-mediated immunity is usually involved in DGS with
a decrease in T-cell numbers and function.21 However,
disorders of humoral immunity also occur. The severity of
immunodeficiency varies for affected patients, and causes
different degrees of viral infections of the upper and lower
respiratory tract. The term “complete DGS” in contrast to
“partial DGS” is at the extreme end of the spectrum of
immunodeficiency, which is characterized by thymic apla-
sia and absent T cells. These victims require aggressive
immunotherapy and sometimes thymic transplantation.22
Mild T-cell deficiency and normal levels of immunoglobu-
lins were observed in our patient, which explains why there
was no significant infection and adverse effects from
vaccinations in her past history. Palate abnormality is
another important issue of DGS, and about 70% of such
cases have velopharyngeal incompetence.10 Abnormal
anatomy and functionality may cause problems such as
feeding difficulties, delayed speech development, sinusitis,
otitis media, and conductive hearing loss. Impaired speech
and language development starts from a preschool age and
continues if no intervention is available. To decide on an
optimal therapy, a full evaluation of velopharyngeal insuf-
ficiency, and speech and language skills should be initiated
without delay.
In conclusion, DGS is not really a rare disease. Hypo-
calcemia may not be present during the neonatal period,
and can occur anytime in childhood and even in adulthood.
Cardiovascular malformation is one of the most common
manifestations of DGS, and its typical conotruncal cardiac
defects are usually regarded as a clue to the diagnosis.
Nonetheless, the group of DGS in the absence of cardio-
vascular malformation may be underestimated when they
present only with extracardiac stigmata, especially minor
facial dysmorphism. As health practitioners, it is our duty to
identify the affected victims who are under-recognized in
the general population, and to conduct thorough investi-
gations and provide appropriate rehabilitation as soon as
possible. MLPA is a rapid, economical, and reliable alter-
native method for establishing the diagnosis of 22q11.2
deletion syndrome.
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